Jefferies raises Tarsus Pharmaceuticals price target to $105, keeps Buy
Jefferies maintained a Buy rating on Tarsus Pharmaceuticals while raising its price target to $105.00 per share from $88.00, according to Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.